No products in the cart
Tesamorelin (5mg & 10mg)
$38.00 – $73.00
Tesameorelin peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
|Price||$36.10 – $69.35||$34.20 – $65.70|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Tesamorelin Peptide?
Tesamorelin is a chemically altered growth hormone-releasing hormone (GHRH) analog. This peptide is a trans-3-hexanoic acid version of natural GHRH. It has been heavily researched for its potential to enhance peripheral nerve regeneration and improve mild cognitive impairment (MCI), the precursor to dementia. Tesamorelin appears to mediate the positive influence of GHRH and other GHRH analogs such as GRF (1-29), CJC-1295, and sermorelin. The trans-3-hexanoic acid modification may increase its blood plasma stability and half-life. Both Tesamorelin and CJC-1295 appear to maintain the physiological effects of GHRH and display limited side effects compared to other analogs, which typically disrupt the physiological rhythm of GH release.
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.77 g/mol
PubChem: CID 44147413
CAS Number: 901758-09-6
Tesamorelin and Growth Hormone Deficiency, HIV
Highly active antiretroviral therapy (HAART) triggers endocrine and metabolic disorders, including growth hormone (GH) deficiency. The HIV infection alters the pituitary gland function and causes GH deficiency in one-third of HAART patients. Tesamorelin research suggests the peptide may be a safer and more effective treatment for improving GH levels than the administration of exogenous GH, particularly in HIV-positive individuals.
Tesamorelin and Cardiac Disease
Adiposity and antiretroviral drugs put HIV-positive individuals at increased risk of developing cardiovascular disease (CVD). Hence prevention of CVD is of crucial concern in such patients, and statins have been the drug of choice. Tesamorelin studies posit that the peptide reduces lipodystrophy and triglyceride, total cholesterol, and non-HDL-C in HIV-positive patients. Ectopic fat deposition is involved in inflammation, which increases the risk of CVD. Adipose tissue deposition in visceral organs, epicardium, and liver enhance CVD risk. The peptide thus may decrease inflammatory response by controlling excess adiposity. The researchers note that “HIV-infected patients receiving tesamorelin with ≥8% reduction in VAT have significantly improved triglyceride levels, adiponectin levels, and preservation of glucose homeostasis over 52 weeks of treatment.”
Tesamorelin and Lypodystrophy
Tesamorelin is principally researched in relation to treating HIV-associated lipodystrophy caused by a viral infection and the adverse effect of antiretroviral therapy. Patients suffering from lipodystrophy rely on diet, exercise, some ineffective medications, and surgery as a last measure. The peptide appeared to reduce adiposity by about 20% in patients. The researchers also note that “The odds of response of VAT ‹140 cm2 was 3.9 times greater for tesamorelin-treated patients than that of patients receiving placebo.”
Tesamorelin and Peripheral Nerve Damage
Peripheral nerve damage can be caused by injury, diabetes, or surgical interventions. It triggers debilitating motor and sensory function challenges in the affected parts. There is very limited intervention as nerve cells are tough to regenerate. Studies show that growth hormone manipulation can improve peripheral nerve injury and increase both rate and extent of healing. Tesamorelin is being considered for such intervention.
Tesamorelin Investigated in Dementia
GHRH analogs, including Tesamorelin, have been researched for their potential to improve cognitive ability in patients suffering from the early stages of dementia. A randomized, double-blind, placebo-controlled study was conducted with a large cohort over a period of twenty weeks at the University of Washington School of Medicine. The study observed that Tesamorelin and other GHRH analogs may influence dementia by increasing gamma-aminobutyric acid (GABA) in the brain and decreasing myo-insoitol (MI). These findings on the potential of Tesamorelin use in the treatment of dementia also suggest new avenues for research to find a cure. The peptide is a sought-after molecule for clinical trials. It is presently being evaluated for its ability to regulate cardiovascular disease in HIV, enhance healing of peripheral nerves following injury, and slow the progression of dementia. Clinical trials are being conducted in several different areas. Experimental studies report that Tesamorelin appears to exhibit minimal side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice. The dosage for use in mice (per kg) does not scale to humans. Tesamorelin is sold at Biotech Peptides for educational and scientific research and not for human use.
- Rochira, V., & Guaraldi, G. (2017). Growth hormone deficiency and human immunodeficiency virus. Best practice & research. Clinical endocrinology & metabolism, 31(1), 91–111. doi:10.1016/j.beem.2017.02.006.
- Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine, 357(23), 2359–2370. doi:10.1056/NEJMoa072375.
- Stanley, T. L., Falutz, J., Marsolais, C., Morin, J., Soulban, G., Mamputu, J. C., Assaad, H., Turner, R., & Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 54(11), 1642–1651. doi:10.1093/cid/cis251.
- Mangili, A., Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PloS one, 10(10), e0140358. doi:10.1371/journal.pone.0140358.
- Tuffaha, S. H., Singh, P., Budihardjo, J. D., Means, K. R., Higgins, J. P., Shores, J. T., Salvatori, R., Höke, A., Lee, W. P., & Brandacher, G. (2016). Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert opinion on therapeutic targets, 20(10), 1259–1265. doi:10.1080/14728222.2016.1188079.
- Friedman, S. D., Baker, L. D., Borson, S., Jensen, J. E., Barsness, S. M., Craft, S., Merriam, G. R., Otto, R. K., Novotny, E. J., & Vitiello, M. V. (2013). Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA neurology, 70(7), 883–890. doi:10.1001/jamaneurol.2013.1425.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.
|Please select a size||